報告摘要

The global Multiple Sclerosis Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032. North America: the Multiple Sclerosis Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Multiple Sclerosis Therapeutics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Multiple Sclerosis Therapeutics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Multiple Sclerosis Therapeutics include Biogen Idec, Sanofi Genzyme, Teva Pharmaceuticals, AbbVie, Bayer, Pfizer, Merck and Novartis, among others; in 2025, the top three vendors together accounted for approximately % of global revenue. Report Scope This report quantifies the global Multiple Sclerosis Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032. It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Multiple Sclerosis Therapeutics. Key Companies & Market Share Insights This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking. Multiple Sclerosis Therapeutics Market by Company Biogen Idec Sanofi Genzyme Teva Pharmaceuticals AbbVie Bayer Pfizer Merck Novartis Multiple Sclerosis Therapeutics Segment by Type Beta Interferon Monoclonal Antibodies Antineoplastic Agents Corticosteroids Others Multiple Sclerosis Therapeutics Segment by Application Hospital Pharmacies Retail Pharmacies e-Commerce Multiple Sclerosis Therapeutics Segment by Region North America United States Canada Europe Germany France U.K. Italy Spain Russia Netherlands Nordic Countries Asia-Pacific China Japan South Korea India Australia China Taiwan Southeast Asia South America Mexico Brazil Argentina Middle East & Africa Saudi Arabia Israel United Arab Emirates Turkey Iran Egypt Key Drivers & Barriers High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects. Reasons to Buy This Report 1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Sclerosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market. 2. This report will help stakeholders to understand the global industry status and trends of Multiple Sclerosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities. 3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition. 4. This report stays updated with novel technology integration, features, and the latest developments in the market 5. This report helps stakeholders to gain insights into which regions to target globally 6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Sclerosis Therapeutics. 7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution. Chapter Outline Chapter 1: Research objectives, research methods, data sources, data cross-validation; Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term. Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry. Chapter 6: Detailed analysis of Multiple Sclerosis Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc. Chapter 13: The main points and conclusions of the report.

目錄 Table of Contents

1 Preface 1.1 Scope of Report 1.2 Reasons for Doing This Study 1.3 Research Methodology 1.4 Research Process 1.5 Data Source 1.5.1 Secondary Sources 1.5.2 Primary Sources 2 Market Overview 2.1 Product Definition 2.2 Multiple Sclerosis Therapeutics by Type 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) 2.2.2 Beta Interferon 2.2.3 Monoclonal Antibodies 2.2.4 Antineoplastic Agents 2.2.5 Corticosteroids 2.2.6 Others 2.3 Multiple Sclerosis Therapeutics by Application 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) 2.3.2 Hospital Pharmacies 2.3.3 Retail Pharmacies 2.3.4 e-Commerce 2.4 Assumptions and Limitations 3 Multiple Sclerosis Therapeutics Breakdown Data by Type 3.1 Global Multiple Sclerosis Therapeutics Historic Market Size by Type (2021-2026) 3.2 Global Multiple Sclerosis Therapeutics Forecasted Market Size by Type (2027-2032) 4 Multiple Sclerosis Therapeutics Breakdown Data by Application 4.1 Global Multiple Sclerosis Therapeutics Historic Market Size by Application (2021-2026) 4.2 Global Multiple Sclerosis Therapeutics Forecasted Market Size by Application (2027-2032) 5 Global Growth Trends 5.1 Global Multiple Sclerosis Therapeutics Market Perspective (2021-2032) 5.2 Global Multiple Sclerosis Therapeutics Growth Trends by Region 5.2.1 Global Multiple Sclerosis Therapeutics Market Size by Region: 2021 VS 2025 VS 2032 5.2.2 Multiple Sclerosis Therapeutics Historic Market Size by Region (2021-2026) 5.2.3 Multiple Sclerosis Therapeutics Forecasted Market Size by Region (2027-2032) 5.3 Multiple Sclerosis Therapeutics Market Dynamics 5.3.1 Multiple Sclerosis Therapeutics Industry Trends 5.3.2 Multiple Sclerosis Therapeutics Market Drivers 5.3.3 Multiple Sclerosis Therapeutics Market Challenges 5.3.4 Multiple Sclerosis Therapeutics Market Restraints 6 Market Competitive Landscape by Players 6.1 Global Top Multiple Sclerosis Therapeutics Players by Revenue 6.1.1 Global Top Multiple Sclerosis Therapeutics Players by Revenue (2021-2026) 6.1.2 Global Multiple Sclerosis Therapeutics Revenue Market Share by Players (2021-2026) 6.2 Global Multiple Sclerosis Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025 6.3 Global Key Players of Multiple Sclerosis Therapeutics Head Office and Area Served 6.4 Global Multiple Sclerosis Therapeutics Players, Product Type & Application 6.5 Global Multiple Sclerosis Therapeutics Manufacturers Established Date 6.6 Global Multiple Sclerosis Therapeutics Market CR5 and HHI 6.7 Global Players Mergers & Acquisition 7 North America 7.1 North America Multiple Sclerosis Therapeutics Market Size (2021-2032) 7.2 North America Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 7.3 North America Multiple Sclerosis Therapeutics Market Size by Country (2021-2026) 7.4 North America Multiple Sclerosis Therapeutics Market Size by Country (2027-2032) 7.5 United States 7.5 United States 7.6 Canada 7.7 Mexico 8 Europe 8.1 Europe Multiple Sclerosis Therapeutics Market Size (2021-2032) 8.2 Europe Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 8.3 Europe Multiple Sclerosis Therapeutics Market Size by Country (2021-2026) 8.4 Europe Multiple Sclerosis Therapeutics Market Size by Country (2027-2032) 8.5 Germany 8.6 France 8.7 U.K. 8.8 Italy 8.9 Spain 8.10 Russia 8.11 Netherlands 8.12 Nordic Countries 9 Asia-Pacific 9.1 Asia-Pacific Multiple Sclerosis Therapeutics Market Size (2021-2032) 9.2 Asia-Pacific Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 9.3 Asia-Pacific Multiple Sclerosis Therapeutics Market Size by Country (2021-2026) 9.4 Asia-Pacific Multiple Sclerosis Therapeutics Market Size by Country (2027-2032) 9.5 China 9.6 Japan 9.7 South Korea 9.8 India 9.9 Australia 9.10 China Taiwan 9.11 Southeast Asia 10 South America 10.1 South America Multiple Sclerosis Therapeutics Market Size (2021-2032) 10.2 South America Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 10.3 South America Multiple Sclerosis Therapeutics Market Size by Country (2021-2026) 10.4 South America Multiple Sclerosis Therapeutics Market Size by Country (2027-2032) 10.5 Brazil 10.6 Argentina 10.7 Chile 10.8 Colombia 10.9 Peru 11 Middle East & Africa 11.1 Middle East & Africa Multiple Sclerosis Therapeutics Market Size (2021-2032) 11.2 Middle East & Africa Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 11.3 Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Country (2021-2026) 11.4 Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Country (2027-2032) 11.5 Saudi Arabia 11.6 Israel 11.7 United Arab Emirates 11.8 Turkey 11.9 Iran 11.10 Egypt 12 Players Profiled 12.1 Biogen Idec 12.1.1 Biogen Idec Company Information 12.1.2 Biogen Idec Business Overview 12.1.3 Biogen Idec Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) 12.1.4 Biogen Idec Multiple Sclerosis Therapeutics Product Portfolio 12.1.5 Biogen Idec Recent Developments 12.2 Sanofi Genzyme 12.2.1 Sanofi Genzyme Company Information 12.2.2 Sanofi Genzyme Business Overview 12.2.3 Sanofi Genzyme Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) 12.2.4 Sanofi Genzyme Multiple Sclerosis Therapeutics Product Portfolio 12.2.5 Sanofi Genzyme Recent Developments 12.3 Teva Pharmaceuticals 12.3.1 Teva Pharmaceuticals Company Information 12.3.2 Teva Pharmaceuticals Business Overview 12.3.3 Teva Pharmaceuticals Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) 12.3.4 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Product Portfolio 12.3.5 Teva Pharmaceuticals Recent Developments 12.4 AbbVie 12.4.1 AbbVie Company Information 12.4.2 AbbVie Business Overview 12.4.3 AbbVie Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) 12.4.4 AbbVie Multiple Sclerosis Therapeutics Product Portfolio 12.4.5 AbbVie Recent Developments 12.5 Bayer 12.5.1 Bayer Company Information 12.5.2 Bayer Business Overview 12.5.3 Bayer Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) 12.5.4 Bayer Multiple Sclerosis Therapeutics Product Portfolio 12.5.5 Bayer Recent Developments 12.6 Pfizer 12.6.1 Pfizer Company Information 12.6.2 Pfizer Business Overview 12.6.3 Pfizer Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) 12.6.4 Pfizer Multiple Sclerosis Therapeutics Product Portfolio 12.6.5 Pfizer Recent Developments 12.7 Merck 12.7.1 Merck Company Information 12.7.2 Merck Business Overview 12.7.3 Merck Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) 12.7.4 Merck Multiple Sclerosis Therapeutics Product Portfolio 12.7.5 Merck Recent Developments 12.8 Novartis 12.8.1 Novartis Company Information 12.8.2 Novartis Business Overview 12.8.3 Novartis Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) 12.8.4 Novartis Multiple Sclerosis Therapeutics Product Portfolio 12.8.5 Novartis Recent Developments 13 Report Conclusion 14 Disclaimer

圖表清單 List of Tables & Figures

List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Multiple Sclerosis Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Multiple Sclerosis Therapeutics Revenue Market Share by Type (2021-2026) Table 7. Global Multiple Sclerosis Therapeutics Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Multiple Sclerosis Therapeutics Revenue Market Share by Type (2027-2032) Table 9. Global Multiple Sclerosis Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Multiple Sclerosis Therapeutics Revenue Market Share by Application (2021-2026) Table 11. Global Multiple Sclerosis Therapeutics Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Multiple Sclerosis Therapeutics Revenue Market Share by Application (2027-2032) Table 13. Global Multiple Sclerosis Therapeutics Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Multiple Sclerosis Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Multiple Sclerosis Therapeutics Market Share by Region (2021-2026) Table 16. Global Multiple Sclerosis Therapeutics Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Multiple Sclerosis Therapeutics Market Share by Region (2027-2032) Table 18. Multiple Sclerosis Therapeutics Industry Trends Table 19. Multiple Sclerosis Therapeutics Industry Drivers Table 20. Multiple Sclerosis Therapeutics Industry Opportunities and Challenges Table 21. Multiple Sclerosis Therapeutics Market Restraints Table 22. Global Top Multiple Sclerosis Therapeutics Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Multiple Sclerosis Therapeutics Revenue Market Share by Players (2021-2026) Table 24. Global Multiple Sclerosis Therapeutics Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Multiple Sclerosis Therapeutics, Headquarters and Area Served Table 26. Global Multiple Sclerosis Therapeutics Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Multiple Sclerosis Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Multiple Sclerosis Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Multiple Sclerosis Therapeutics Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Multiple Sclerosis Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Multiple Sclerosis Therapeutics Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Multiple Sclerosis Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Multiple Sclerosis Therapeutics Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Multiple Sclerosis Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Multiple Sclerosis Therapeutics Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Country (2027-2032) & (US$ Million) Table 45. Biogen Idec Company Information Table 46. Biogen Idec Business Overview Table 47. Biogen Idec Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) & (US$ Million) Table 48. Biogen Idec Multiple Sclerosis Therapeutics Product Portfolio Table 49. Biogen Idec Recent Developments Table 50. Sanofi Genzyme Company Information Table 51. Sanofi Genzyme Business Overview Table 52. Sanofi Genzyme Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) & (US$ Million) Table 53. Sanofi Genzyme Multiple Sclerosis Therapeutics Product Portfolio Table 54. Sanofi Genzyme Recent Developments Table 55. Teva Pharmaceuticals Company Information Table 56. Teva Pharmaceuticals Business Overview Table 57. Teva Pharmaceuticals Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) & (US$ Million) Table 58. Teva Pharmaceuticals Multiple Sclerosis Therapeutics Product Portfolio Table 59. Teva Pharmaceuticals Recent Developments Table 60. AbbVie Company Information Table 61. AbbVie Business Overview Table 62. AbbVie Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) & (US$ Million) Table 63. AbbVie Multiple Sclerosis Therapeutics Product Portfolio Table 64. AbbVie Recent Developments Table 65. Bayer Company Information Table 66. Bayer Business Overview Table 67. Bayer Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) & (US$ Million) Table 68. Bayer Multiple Sclerosis Therapeutics Product Portfolio Table 69. Bayer Recent Developments Table 70. Pfizer Company Information Table 71. Pfizer Business Overview Table 72. Pfizer Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) & (US$ Million) Table 73. Pfizer Multiple Sclerosis Therapeutics Product Portfolio Table 74. Pfizer Recent Developments Table 75. Merck Company Information Table 76. Merck Business Overview Table 77. Merck Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) & (US$ Million) Table 78. Merck Multiple Sclerosis Therapeutics Product Portfolio Table 79. Merck Recent Developments Table 80. Novartis Company Information Table 81. Novartis Business Overview Table 82. Novartis Revenue in Multiple Sclerosis Therapeutics Business (2021-2026) & (US$ Million) Table 83. Novartis Multiple Sclerosis Therapeutics Product Portfolio Table 84. Novartis Recent Developments Table 85. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Multiple Sclerosis Therapeutics Product Image Figure 5. Global Multiple Sclerosis Therapeutics Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Multiple Sclerosis Therapeutics Market Share by Type: 2025 VS 2032 Figure 7. Beta Interferon Product Figure 8. Monoclonal Antibodies Product Figure 9. Antineoplastic Agents Product Figure 10. Corticosteroids Product Figure 11. Others Product Figure 12. Global Multiple Sclerosis Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Multiple Sclerosis Therapeutics Market Share by Application: 2025 VS 2032 Figure 14. Hospital Pharmacies Product Figure 15. Retail Pharmacies Product Figure 16. e-Commerce Product Figure 17. Global Multiple Sclerosis Therapeutics Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 18. Global Multiple Sclerosis Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Multiple Sclerosis Therapeutics Market Share by Region: 2025 VS 2032 Figure 20. Global Multiple Sclerosis Therapeutics Market Share by Players in 2025 Figure 21. Global Multiple Sclerosis Therapeutics Manufacturers Established Date Figure 22. Global Top 5 and 10 Multiple Sclerosis Therapeutics Players Market Share by Revenue in 2025 Figure 23. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 24. North America Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Multiple Sclerosis Therapeutics Market Share by Country (2021-2032) Figure 26. United States Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Canada Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. Mexico Multiple Sclerosis Therapeutics Market Share by Country (2021-2032) Figure 29. Europe Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Multiple Sclerosis Therapeutics Market Share by Country (2021-2032) Figure 31. Germany Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. France Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. U.K. Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Italy Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Spain Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Russia Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Netherlands Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Nordic Countries Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Multiple Sclerosis Therapeutics Market Share by Country (2021-2032) Figure 41. China Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. Japan Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. South Korea Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. India Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. India Multiple Sclerosis Therapeutics Market Share by Country (2021-2032) Figure 46. Australia Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. China Taiwan Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. Southeast Asia Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. South America Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. South America Multiple Sclerosis Therapeutics Market Share by Country (2021-2032) Figure 51. Brazil Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Argentina Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Chile Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Colombia Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 55. Peru Multiple Sclerosis Therapeutics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 56. Biogen Idec Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2021-2026) Figure 57. Sanofi Genzyme Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2021-2026) Figure 58. Teva Pharmaceuticals Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2021-2026) Figure 59. AbbVie Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2021-2026) Figure 60. Bayer Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2021-2026) Figure 61. Pfizer Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2021-2026) Figure 62. Merck Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2021-2026) Figure 63. Novartis Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2021-2026)

Single User	$2,950 USD
Multi User	$4,430 USD
Enterprise	$5,900 USD

Multiple Sclerosis Therapeutics Industry Research Report 2026

授權報價

報告摘要

提及公司